Medical Management of Glaucoma in the 21st Century from a Canadian Perspective.
Medical Management of Glaucoma in the 21st Century from a Canadian Perspective.
复制标题
DOI：
10.1155/2016/6509809
复制
发表时间：
2016
影响因子：
1.9
通讯作者：
Day R
中科院分区：
文献类型：
--
作者：
Harasymowycz P;Birt C;Gooi P;Heckler L;Hutnik C;Jinapriya D;Shuba L;Yan D;Day R
青光眼是一个医学术语，描述一组进行性视神经病变，其特征是视网膜神经节细胞和视网膜神经纤维层变性，导致视神经乳头改变。青光眼是世界范围内不可逆视力丧失的主要原因。随着人口老龄化，预计青光眼的患病率将继续增加。尽管成像和视野测试技术的最新进展允许建立早期诊断和治疗开始，但大量青光眼患者未被诊断并且在其疾病过程的晚期出现。这可能导致不可逆转的视力丧失，生活质量下降和更高的社会经济负担。青光眼治疗方法的选择应基于仔细的眼部检查、患者病史、合并症的存在以及对伴随全身治疗的认识。治疗还应根据患者的需要和偏好进行个性化。该治疗领域的最新发展需要重新审视治疗算法并整合传统和新型方法，以确保最佳的视觉效果。本文概述了加拿大青光眼医疗管理的最新发展和实践趋势。手术治疗的讨论超出了本文的范围。
Glaucoma is a medical term describing a group of progressive optic neuropathies characterized by degeneration of retinal ganglion cells and retinal nerve fibre layer and resulting in changes in the optic nerve head. Glaucoma is a leading cause of irreversible vision loss worldwide. With the aging population it is expected that the prevalence of glaucoma will continue to increase. Despite recent advances in imaging and visual field testing techniques that allow establishment of earlier diagnosis and treatment initiation, significant numbers of glaucoma patients are undiagnosed and present late in the course of their disease. This can lead to irreversible vision loss, reduced quality of life, and a higher socioeconomic burden. Selection of therapeutic approaches for glaucoma should be based on careful ocular examination, patient medical history, presence of comorbidities, and awareness of concomitant systemic therapies. Therapy should also be individualized to patients' needs and preferences. Recent developments in this therapeutic field require revisiting treatment algorithms and integration of traditional and novel approaches in order to ensure optimal visual outcomes. This article provides an overview of recent developments and practice trends in the medical management of glaucoma in Canada. A discussion of the surgical management is beyond the scope of this paper.
登录
查看更多内容
影响因子：
4.4
作者：
Berdahl JP;Fautsch MP;Stinnett SS;Allingham RR
通讯作者：
Allingham RR
影响因子：
3.8
作者：
CHRAI, SS;MAKOID, MC;ROBINSON, JR
通讯作者：
ROBINSON, JR
影响因子：
2.3
作者：
Day, Douglas G.;Hollander, David A.
通讯作者：
Hollander, David A.
社会经济地位是加拿大青光眼晚期发病的一个风险因素
DOI：
10.1016/j.jcjo.2012.10.003
发表时间：
2013-04-01
影响因子：
4.2
作者：
Buys, Yvonne M.;Jin, Ya-Ping
通讯作者：
Jin, Ya-Ping
DOI：
10.1016/j.jcjo.2011.06.013
发表时间：
2011-08-01
影响因子：
4.2
作者：
Anraku, Ayako;Jin, Ya-Ping;Trope, Graham E.
通讯作者：
Trope, Graham E.